MedTrace Logo

Morbidity and Mortality of Hepatitis E Virus Infections in Belgium

NCT04670419 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 280

Last updated 2020-12-17

No results posted yet for this study

Summary

Hepatitis E Virus (HEV) infections are emerging in the Western world with a predominance of HEV genotype (gt) 3. Except for age older than 50 years, male gender, chronic liver disease and immunosuppressed status, no correlators with clinical outcomes have been identified so far. With this study, we want to examine viral factors associated with the morbidity and mortality of HEV infections in Belgium as well as find correlators with clinical outcomes.

Conditions

  • Hepatitis E

Interventions

OTHER

Viral clade

Disease outcomes are compared for patients infected with 2 different clades of a HEV gt 3 infection

Sponsors & Collaborators

  • Sciensano

    collaborator OTHER_GOV

  • KU Leuven

    collaborator OTHER

  • University Hospital, Antwerp

    lead OTHER

Principal Investigators

  • Thomas Vanwolleghem, MD PhD · University Hospital, Antwerp

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-01
Primary Completion
2018-06-30
Completion
2018-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04670419 on ClinicalTrials.gov